- Projects & figures
- News & Events
- Managing your project
- About ERC
Tamoxifen, a drug used in breast cancer treatment, may be repositioned to treat pancreatic cancer
Pancreatic cancer is the 4th leading cause of death by cancer in Europe. It has a very low survival rate with less than 1 per cent of sufferers surviving for 10 or more years. Over the last 40 years the survival rate has not significantly changed and finding an effective therapy has become a pressing challenge in cancer research. A team based at Imperial College London led by Armando Del Río Hernández, has now demonstrated that a well-known drug could be effective to fight this deadly and other forms of cancer, such as liver cancer.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
Dr Málnási-Csizmadia focuses on enzymes, proteins essential for body functions, and the largely unexplored intricate mechanisms underlying their activity. His recent findings could open the way to a ground-breaking development in pharmacology, especially in targeted cancer therapy.
Scientists at the University of Manchester (UK) hope a major breakthrough could lead to more effective methods for detoxifying dangerous pollutants like PCBs (polychlorinated biphenyls) and dioxins. The result is a culmination of 15 years of research and has been published in Nature on 19 October. It details how certain organisms manage to lower the toxicity of pollutants.
Conducting research in small RNAs, Dr. Ramesh Pillai attempts to understand how the genome protects itself from an internal threat, namely ‘transposons’ or ‘jumping genes’ which can cause mutations. Awarded an ERC Starting grant in 2010, Dr. Pillai is based at the European Molecular Biological Laboratory, Grenoble (France).
The answer to why some people age earlier than others, or why they develop cancer, could lie at the very end sections of our DNA: the telomeres.